Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers. Read why I now taper my rating for CRBU ...
Sporting News5d
Chargers vs. Chiefs Series History: When was the last time L.A. beat the champs?
The Chargers have endured a losing streak against the Kansas City Chiefs and ending that is likely at the top of Jim Harbaugh ...
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 ...
averyjournal9d
Friedkin Group reach deal to buy Everton
Everton announced on Monday that the US-based Friedkin Group has reached an agreement to buy Farhad Moshiri's majority stake ...
clinicaltrialsarena26d
Boehringer and CDR-Life report data from geographic atrophy treatment trial
The trial assessed the tolerability, safety, and pharmacokinetics of BI 771716 in GA patients aged 50 years and above. Credit: Max4e Photo/Shutterstock. Boehringer Ingelheim and CDR-Life have reported ...
lupusnewstoday27d
FDA grants fast track designation to CAR T-cell therapy for SLE
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Caribou Biosciences‘ CAR T-cell therapy CB-010 for systemic lupus erythematosus (SLE) — the most common form of lupus ...
Investing28d
Analyst reaffirms Buy on Caribou Biosciences stock after FDA Fast Track designations
The therapies in question, CB-010 and CB-012, address significant medical needs. CB-010 is aimed at treating refractory systemic lupus erythematosus (SLE), while CB-012 targets relapsed or ...
Investing29d
FDA fast tracks Caribou's gene-edited CAR-T therapies
CB-010 is an allogeneic anti-CD19 CAR-T cell therapy targeting refractory systemic lupus erythematosus (SLE), including lupus nephritis (LN) and extrarenal lupus (ERL). The GALLOP Phase 1 clinical ...
Mena FN29d
Caribou Biosciences Announces The FDA Has Granted Fast Track Designations To CB-010 In Refractory SLE And To CB-012 In Relapsed Or Refractory AML
CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 -- -- CB-012 AMpLify Phase 1 trial advancing in dose escalation -- BERKELEY, Calif., Sept. 03 ...
Yahoo Finance29d
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
CB-010, an allogeneic anti-CD19 CAR-T cell therapy, will be evaluated in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL), subcategories of SLE.
Business Insider29d
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations ...